252 related articles for article (PubMed ID: 27666548)
41. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
[TBL] [Abstract][Full Text] [Related]
42. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis.
Yang HJ; Gu Y; Chen C; Xu C; Bao YX
Clin Chem Lab Med; 2011 Jun; 49(6):1039-46. PubMed ID: 21649553
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer.
Naumnik W; Chyczewska E; Izycki T; Ossolinska M
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():88-90. PubMed ID: 15638385
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
[TBL] [Abstract][Full Text] [Related]
46. Clinical implications for pro-GRP in small cell lung cancer. A single center experience.
Cavalieri S; Morelli D; Martinetti A; Galli G; Nichetti F; de Braud F; Platania M
Int J Biol Markers; 2018 Jan; 33(1):55-61. PubMed ID: 28967066
[TBL] [Abstract][Full Text] [Related]
47. New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.
Nisman B; Nechushtan H; Biran H; Peled N; Gantz-Sorotsky H; Doviner V; Perelman M; Bar J; Onn A; Uziely B; Peretz T
Br J Cancer; 2016 Feb; 114(4):469-76. PubMed ID: 26812573
[TBL] [Abstract][Full Text] [Related]
48. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
49. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
50. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
51. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Significance of Combined Biomarkers in Small Cell Lung Cancer.
Wang L; Cao L; Jiang R; Huang D
Clin Lab; 2020 Sep; 66(9):. PubMed ID: 32902217
[TBL] [Abstract][Full Text] [Related]
53. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
Wang C; Jin S; Xu S; Cao S
Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
[TBL] [Abstract][Full Text] [Related]
54. ProGRP: a new biomarker for small cell lung cancer.
Molina R; Filella X; Augé JM
Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
[TBL] [Abstract][Full Text] [Related]
55. [Utility of Multiple Increased Lung Cancer Tumor Markers in Treatment of Patients with Advanced Lung Adenocarcinoma].
Peng Y; Wang Y; Hao X; Li J; Liu Y; Wang H
Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):690-694. PubMed ID: 29061216
[TBL] [Abstract][Full Text] [Related]
56. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.
Quoix E; Purohit A; Faller-Beau M; Moreau L; Oster JP; Pauli G
Lung Cancer; 2000 Nov; 30(2):127-34. PubMed ID: 11086206
[TBL] [Abstract][Full Text] [Related]
57. Pro-gastrin-releasing peptide as a marker for the Ewing sarcoma family of tumors.
Honda Y; Katagiri H; Takahashi M; Murata H; Wasa J; Hosaka S; Ishida Y; Ito I; Muramatsu K; Mochizuki T; Matsuyama Y; Yamaguchi K
Int J Clin Oncol; 2019 Nov; 24(11):1468-1478. PubMed ID: 31264078
[TBL] [Abstract][Full Text] [Related]
58. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
[TBL] [Abstract][Full Text] [Related]
59. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
60. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]